16 dic 2016 anni - FDA approved several safety labeling changes
(SLCs) about the serious risks of prescription
opioid analgesics and opioids approved for
medication assisted treatment (MAT) of opioid
addiction including class-wide SLCs for
immediate-release (IR) opioid pain medications,
SLCs for methadone and buprenorphine
products, and class-wide SLCs about the serious
risks associated with the combined use of certain
opioid medications with benzodiazepines or
other central nervous system (CNS) depressants.